Searched for
OPDIVO
Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Zydus Life cleared to sell life-saving cancer drug; SC tells Bristol Myers to map patentsThe Supreme Court has provided Zydus Lifesciences with the go-ahead to launch its cancer drug biosimilar, countering efforts by Bristol Mye...
- Bristol Myers moves SC to stop Zydus from selling biosimilar cancer drugUS firm Bristol Myers Squibb is in the Supreme Court seeking to halt Zydus Lifesciences from manufacturing and selling a biosimilar cancer ...
- Zydus Lifesciences launches world's first nivolumab biosimilar in India, boosting cancer treatment affordabilityAhmedabad-based Zydus Lifesciences has launched Tishtha, the world's first biosimilar of the oncology drug nivolumab, in India. This move s...
- Delhi HC clears Zydus to sell biosimilar of BMS cancer drug NivolumabThe Delhi High Court has permitted Zydus Lifesciences to produce and market a biosimilar cancer drug. This decision comes as the patent for...
- Biocon Biologics to introduce three new biosimilars for cancer treatmentBiocon Biologics will launch three new oncology biosimilars. These include Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab. The com...
- Bristol Myers lines up many launches for India with 'AI' speedBristol Myers Squibb sees India as a major growth driver. The company is investing heavily in AI to speed up drug launches and improve doct...
- Zydus moves Delhi HC against order restraining manufacture, sale of its cancer drugZydus Lifesciences has appealed a Delhi High Court order. The order restricts it from producing a biosimilar of E.R. Squibb's Nivolumab. Sq...
- Zydus Life's plans for cancer biosimilar hit a legal hurdleThe Delhi High Court has granted an interim injunction against Zydus Lifesciences, an Ahmedabad-based drug maker, following a patent infrin...
- Delhi Police bust interstate drug syndicate, seize 348 kg of ganjaDelhi Police have intensified efforts to combat crime, dismantling an interstate drug syndicate and seizing 348 kg of Ganja worth Rs 1.75 c...
- No April Fool's joke: New Zealand hikes benefits, minimum wage and healthcare funding from April 1New Zealand will implement changes from April 1, 2025, affecting benefits, minimum wage, power prices, student loan repayments, and Pharmac...
- Big chase for a cancer drug: The urgent need for affordable Keytruda alternativesKeytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In Ind...
- Cancer drugmaker Bristol Myers to build its largest R&D facility outside US in India by 2025The $100-million facility, inaugurated by Boerner on Monday, is expected to employ over 1,500 employees and will be used to enhance its dru...
- Bristol Myers to buy Mirati for $4.8 billionThe purchase will give a boost to Bristol as patent expirations weigh on sales of its oncology medicines. The company had to slash its reve...
- Blow to Roche's cancer immunotherapy prospects as 2nd trial failsIn a study, a combination of tiragolumab and Roche's established Tecentriq drug did not slow disease progression in newly diagnosed cases o...
- Nikkei ends at 8-week low, US FX comments hit automakers; Softbank sinksThe Nikkei share average ended 1.8 per cent lower at 22,271.30.
- Nikkei edges up to new 27-year high as weaker yen fans earnings hopesThe Nikkei share average ended 0.1 per cent higher at 24,270.62
- Breakthrough cancer drugs all set for India launchThe accelerated regulatory clearances cut the time lines for introductions of the two big brands which may be expected to be introduced by ...
- Medical breakthrough! Aurigene closer to developing cancer treatment capsuleThe Bengaluru-based company is an independent subsidiary of Dr Reddy’s Laboratories and its United States-based partner Curis Inc.
Load More
